Vivos Therapeutics Files Definitive Proxy Statement

TL;DR

Vivos Therapeutics (VVOS) filed its proxy statement - shareholders vote soon on company matters.

AI Summary

Vivos Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 7, 2024. This filing is a standard disclosure required for public companies, typically related to upcoming shareholder meetings where votes on important matters like director elections or corporate actions are held. The filing itself does not contain specific financial transactions or proposals but serves as the official communication to shareholders regarding such events.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and information needed to participate in upcoming company decisions, ensuring transparency and corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not inherently represent new financial risk or opportunity.

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• 0001493152-24-040285 (filing_id) — Accession Number
• 20241007 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — owned shares of common stock, par value $0.0001 per share, of the Company (the “

Filing Documents

• formdef14a.htm (DEF 14A) — 854KB
• formdef14a_001.jpg (GRAPHIC) — 7KB
• proxy_001.jpg (GRAPHIC) — 357KB
• proxy_002.jpg (GRAPHIC) — 462KB
• 0001493152-24-040285.txt ( ) — 1994KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 VIVOS THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: October 7, 2024 Dear Fellow Stockholders: You are cordially invited to attend Vivos Therapeutic, Inc.’s 2024 Annual Meeting of Stockholders (the “ Annual Meeting ”) to be held on November 26, 2024 at 10:00 a.m. Mountain Time. The formal meeting notice and proxy statement for the Annual Meeting are attached. The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, and vote and submit your questions during the Annual Meeting by visiting www.vivos.com/investor-relations/ . We are pleased to utilize the virtual stockholder meeting technology to provide ready access and cost savings for our stockholders and the company. The virtual meeting format allows attendance from any location in the world. Even if you are planning on attending the Annual Meeting online, please promptly submit your proxy vote by Internet, telephone, or, if you received a printed form of proxy in the mail, by completing, dating, signing and returning the enclosed proxy, so your shares will be represented at the Annual Meeting . Instructions on voting your shares are in the accompanying proxy statement you received for the Annual Meeting. Internet voting facilities for stockholders of record will be available 24 hours a day and will close at 11:59 p.m. Mountain Time on November 25, 2024. If you attend the Annual Meeting online and wish to vote at the Annual Meeting, you will be able to do so even if you have previously returned your proxy card. On behalf of our Board of Directors and management, it is my pleasure to express our appreciation for your continued support of Vivos. Sincerely, /s/ R. Kirk Huntsman R. Kirk Huntsman Chairman of the Board and Chief Executive Officer Littleton, Colorado October 7, 2024 YOUR VOTE IS IMPORTANT VOTING YOUR SHARES WILL ENSURE THE PRESENCE OF A QUORUM AT THE ANNUAL MEETING AND WILL SAVE US THE EXPENSE OF FURTHER SOLICITATION. PLEASE PROMPTLY VOTE YOUR SHARES BY FOLLOWING THE INSTRUCTIONS FOR VOTING DESCRIBED IN THE PROXY STATEMENT BY COMPLETING, SIGNING, DATING AND RETURNING YOUR PROXY CARD MAIL, EMAIL OR FAX AS DESCRIBED ON YOUR PROXY CARD. YOU MAY ALSO VOTE VIA THE INTERNET AS DESCRIBED HEREIN. YOUR PROXY, GIVEN BY VOTING PRIOR TO THE ANNUAL MEETING, MAY BE REVOKED PRIOR TO ITS EXERCISE BY ENTERING A NEW VOTE OVER THE INTERNET, FILING WITH OUR SECRETARY PRIOR TO THE ANNUAL MEETING A WRITTEN NOTICE OF REVOCATION OR A DULY EXECUTED PROXY BEARING A LATER DATE, OR BY ATTENDING THE ANNUAL MEETING ONLINE AND VOTING ONLINE. IF YOU HAVE ALREADY VOTED OR DELIVERED YOUR PROXY FOR THE ANNUAL MEETING, YOUR VOTE WILL BE COUNTED, AND YOU DO NOT HAVE TO VOTE YOUR SHARES AGAIN. IF YOU WISH TO CHANGE YOUR VOTE, YOU SHOULD REVOTE YOUR SHARES. ANY STOCKHOLDER ATTENDING THE ANNUAL MEETING ONLINE MAY VOTE EVEN IF HE OR SHE HAS RETURNED A PROXY. VIVOS THERAPEUTICS, INC. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 (844) 672-4357 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 26, 2024 10:00 A.M. MOUNTAIN TIME TO OUR STOCKHOLDERS : NOTICE IS HEREBY GIVEN that the 2024 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Vivos Therapeutics, Inc., a Delaware corporation (“ we ,” “ us

View Full Filing

View this DEF 14A filing on SEC EDGAR